PanGenomic Health Subsidiary Signs Rental Agreement with Psy Integrated Health, Makes Progress Towards Development of Joint Testing Facility
VANCOUVER, BC, February 2, 2023 /CNW/ – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce this following the announcement on January 26, 2023its subsidiary MUJN Diagnostics Inc. (formerly PlantGx Diagnostics Corp.) (“MUJN Diagnostics”), has signed an agreement to lease space at the Empower Health Wellness Center Clinical Facility located by Psy Integrated Health, Inc. (“Psyi”) in Vancouver, BC. This lease represents an important step in the development of a planned joint diagnostic testing facility with Psyi.
“Co-locating a diagnostic testing facility at Empower Health Wellness Center is expected to help both MUJN and Psyi better understand the needs of patients suffering from brain health issues,” said Vincent Lum, CEO of MUJN Diagnostics and co-founder of PanGenomic Health. “We believe the integrated healthcare approach to patient well-being will continue to grow and deliver positive outcomes for clients who have mental health concerns.”
Patrick CallasDirector of Integrated Health, Psy Integrated Health added, “We are delighted to have MUJN Diagnostics in our wellness center and we believe the synergies of the collaboration will lead to innovative new ideas for better patient outcomes in alternative health therapies.”
The lease has an initial term of 6 months and expires August 1st2023. Continue to dated company press release January 26, 2023, MUJN Diagnostics and Psyi continue to work toward a definitive agreement regarding their proposed joint venture to co-develop a brain health-focused biomarker diagnostic service to support patients treated with ketamine-assisted therapy. Further details are expected to be announced upon completion of a definitive agreement for the proposed joint venture. There can be no assurance that the parties will successfully negotiate and enter into a definitive agreement or that the proposed joint venture will proceed in the timeframe currently contemplated, or at all.
About Psy Integrated Health
Psy Integrated Health, Inc., with its flagship wellness facility, Empower Health, is located in the heart of Vancouver, BC. Canada, is a BC clinic management services company founded to accelerate the development of psychedelic assisted therapeutic treatments and integrated health. Psyi offers innovative treatment modalities for clients with a variety of indications. For more information, visit www.psyintegrated.com and www.empowerhealth.ca.
About MUJN diagnosis
MUJN Diagnostics Inc. is a wholly owned subsidiary of PanGenomic Health Inc. and is focused on developing a decision support system for alternative healthcare providers. MUJN’s Decision Support System includes biomarker diagnostics, symptom and treatment tracking, and personalized health analytics with the goal of empowering healthcare providers and their patients to achieve better outcomes.
About PanGenomic Health
PanGenomic Health is a precision healthcare company that has developed a digital self-care platform to provide personalized, evidence-based information about natural treatments. The company’s initial focus is on mental health support. Registered as British Columbia Benefit Company, PanGenomic Health’s mission is to advance and improve the health and well-being of people and society by providing a technology platform that identifies plant-based solutions tailored to each individual’s health profile.
This press release contains certain statements that may be deemed “forward-looking statements”, including statements regarding the services to be provided by PanGenomic and the consideration to be paid to PanGenomic. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended, identify forward-looking statements. Although PanGenomic believes that the expectations and assumptions upon which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements as PanGenomic cannot guarantee that they will prove to be correct. In particular, the proposed diagnostic testing facility is not yet operational and there can be no assurance that MUJN Diagnostics and Psyi will be able to negotiate satisfactory terms for the proposed joint venture and enter into a definitive agreement for the proposed joint venture, or that MUJN Diagnostics and Psyi will be able to develop the planned test add-on service within the expected timeframe, or at all. Because forward-looking statements address future events and conditions, by their nature they involve risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including various risk factors discussed in PanGenomic’s disclosure documents, which can be found under PanGenomic’s profile on www.sedar.com.
The Canadian Securities Exchange has not approved or disapproved the information contained herein and accepts no responsibility for the adequacy or accuracy of this press release.
SOURCE PanGenomic Health Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2023/02/c3939.html
